Description
Indication & Scope
Pembrolizumab Injection (Keytruda®) is a humanized monoclonal antibody targeting PD-1. It blocks the binding between PD-1 and PD-L1/PD-L2, relieves tumor-induced immune suppression and reactivates T cell-mediated anti-tumor immunity to eliminate cancer cells.
- Mechanism
Block PD-1/PD-L1 interaction to restore anti-tumor immune function of T lymphocytes - Drug class
Intravenous anti-PD-1 immune checkpoint inhibitor concentrate - Clinical use
Melanoma, non-small cell lung cancer, head and neck carcinoma, urothelial carcinoma, cervical cancer and MSI-H/dMMR pan-solid tumors
| Generic Name | Pembrolizumab Injection |
| Brand Name | Keytruda® |
| Ingredient | Pembrolizumab |
| Dosage Form | Injection |
| Package | 100mg/4ml/vial |
| Conditions Treated | Unresectable or metastatic melanoma |
| Taboos | Severe hypersensitivity to pembrolizumab or excipients; active autoimmune disorders, pregnancy and lactation |
| Place of origin | Carlow, Ireland |
| Priscription Type | Prescription Drug, Class B Medicare |
| Storage Conditions | Store at 2℃-8℃, protected from light, sealed |
| Manufacturer | MSD Ireland (Carlow) |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | SJ20180019 |
| Approval Date | December 22, 2022 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: Most solid tumors: 200mg once every 3 weeks or 400mg once every 6 weeks via intravenous infusion
Time: Administer as an intravenous infusion over 30 minutes; do not give as rapid bolus or IV push
Interaction: Avoid long-term high-dose systemic corticosteroids and immunosuppressants before treatment, except for managing immune-related adverse events
Side effects: Fatigue, pruritus, rash, hypothyroidism, diarrhea, nausea; severe risks: Immune-related pneumonitis, colitis, hepatitis, endocrinopathies, severe infusion reactions
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What type of antibody is pembrolizumab?
Humanized IgG4 anti-PD-1 monoclonal antibody.
Why is pembrolizumab not classified as chemotherapy?
It is immunotherapy that activates the body’s own immune system to kill tumor cells.
What special monitoring items are required before and during medication?
Thyroid function, liver and renal function, chest imaging for pneumonia screening.
How to know if pembrolizumab is working?
Imaging scans are the primary method to evaluate Keytruda efficacy. Pseudoprogression, where tumors temporarily enlarge then shrink, is possible, so repeated scans are needed during treatment.
Keytruda® | Pembrolizumab Injection | Metastatic Melanoma | DengYueRX
INN: Pembrolizumab
Indications: Metastatic Melanoma
Dosage Form: Injection
Strength: 100mg/4ml/Vial
Original price was: $4,517.14.$3,839.57Current price is: $3,839.57.
